-
Comprehensive Report Highlights Efforts To Advance Diversity, Equity, Inclusion, Sustainable Business Practices and Corporate Governance
SOUTH SAN FRANCISCO, Calif., February 01, 2022 (GLOBE NOVELSWIRE) — Allogene Therapeutics, Inc., a clinical-stage biotechnology firm pioneering the development allogeneic CART (AlloCART) products for patients with cancer, published its first publicly available information today. ESG report. The report outlines the Company’s commitment to corporate integrity, sustainable business operations, and highlights its priorities, employees, the environment, patients, as well as increasing their access to potentially life-saving products.
Leadership comes in many different forms. The Allogene community understands that while we are working to deliver the first AlloCART products for cancer to patients we can also positively affect employees and the environment. David Chang, Ph.D. is President, Chief Executive Officer, and Co-Founder at Allogene. We are proud to have made so much progress in the four years since our inception. We are excited about the possibility of doing even more together. Our first ESG Report represents our shared commitment towards sustainable growth as leaders in the field of cell therapy.
The full ESG reportThis information is available on both the Culture page and in the Investor Relations section.
Highlights from the ESG report highlight Allogenes commitment:
-
Access to CAR Therapy Therapy: Allogeneic ART T can be used to treat a greater number of patients, at earlier stages and for more types of cancer than autologous CART therapies.
-
Create a diverse and inclusive workplace The Company is proud to be a diverse company and works hard to provide opportunities for underrepresented minorities. The Company established a Diversity, Equity and Inclusion (DEI) Committee in 2020. PolicyIt also confirms its commitment to DEI initiatives. Recruitment efforts are made to attract candidates from underrepresented group and the Company has implemented interview procedures to guard against unconscious bias.
-
Fostering a One Allogene Culture: The Company was established in 2021. One Allogene an initiative that defines its culture. One AllogeneThis is evident in every department of the company, including DEI initiatives, employee education, manager training, performance evaluations, peer recognition, career advancement and wellness programs, as well as manager orientation and education.
-
Prioritizing Environmental Sustainability: The Company is committed to protecting the environment and uses renewable energy sources to reduce greenhouse gases. Cell Forge 1, the Company’s state of the art cell manufacturing facility, was designed and constructed to be efficient. It also uses 100% renewable energy. Cell Forge 1 is expected earn LEED Gold certification for design and operation in 2022.
-
Following the highest ethical standards The December 2021 Company Board of Directors and Nominating and Corporate Governance Committee approved an amendment to their charter to oversee ESG matters. The Committee is also responsible for reporting to the Board about ESG matters.
About Allogene Therapeutics
Allogene Therapeutics is a clinical stage biotechnology company based in South San Francisco. It pioneers the development of Allogeneic chimeric Antigen Receptor T Cell (AlloCAR T), products for cancer. Allogene has a strong management team that has extensive experience in cell therapy. The company is developing a pipeline off-the shelf CAR T cell candidate candidates to help them deliver cell therapy on-demand, more reliably and at a larger scale to more patients. For more information, visit www.allogene.com and follow @AllogeneTx Twitter or LinkedIn.
Cautionary Note: Forward-Looking Statements
Forward-looking statements are made in this press release and in the ESG report for the Private Securities Litigation Reform Act of 2015. In some cases, the ESG report and press release may use terms such “predicts,”” “believes,”,” potential,”,”proposed,”,”continue,”,”estimates,”,”anticipates,”,”expects,” plans,” “intends,” may,” “could,” might,” will,” should,” or other words that convey uncertainty about future events or outcomes. Forward-looking statements can include statements regarding current expectations, intentions, beliefs and projections. There may be differences between Allogenes’ expectations and actual results. This is discussed more fully in Allogenes filings to the Securities and Exchange Commission, including its Form 10-K for 2021. Forward-looking statements in this press release or ESG report are only made as of the date of the press release or ESG report. Allogene disclaims any obligation to update forward-looking statements as a result or new information, future events, etc., after the date this press release and ESG reports.
AlloCAR T trademarked by Allogene Therapeutics, Inc.
Allogene Media/Investor Contacts:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]
Jessica Bernstein
Senior Manager, Corporate and Internal Communications
(310) 781-0577
[email protected]
